Astrazeneca annual dividends paid
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Dividends Paid Growth & History (AZN)
Astrazeneca paid $4.85B in dividends during fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual dividends paid history
| Fiscal year | Period ended | Dividends paid | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.85B | $244.0M | +5.30% |
| 2024 | 2024-12-31 | $4.60B | $115.0M | +2.56% |
| 2023 | 2023-12-31 | $4.49B | $2.0M | +0.04% |
| 2022 | 2022-12-31 | $4.49B | $603.0M | +15.53% |
| 2021 | 2021-12-31 | $3.88B | $214.0M | +5.83% |
| 2020 | 2020-12-31 | $3.67B | $89.0M | +2.49% |
| 2019 | 2019-12-31 | $3.58B | $40.0M | +1.13% |
| 2018 | 2018-12-31 | $3.54B | −$4.0M | −0.11% |
| 2017 | 2017-12-31 | $3.54B | $3.0M | +0.08% |
| 2016 | 2016-12-31 | $3.54B | $3.0M | +0.08% |
| 2015 | 2015-12-31 | $3.54B | — | — |
Astrazeneca quarterly dividends paid
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Dividends paid | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.0M | −$9.0M | −90.00% |
| Q1 2026 | 2026-03-31 | $3.29B | −$60.0M | −1.79% |
| Q2 2025 | 2025-06-30 | $10.0M | — | — |
| Q1 2025 | 2025-03-31 | $3.35B | — | — |
Astrazeneca dividends paid trends
Over the last five fiscal years, Astrazeneca's dividends paid increased from $3.67B to $4.85B, a change of $1.18B. The latest reported quarter, Q2 2026, shows $1.0M.
About the metric
What dividends paid mean
Dividends paid are cash distributions made to shareholders. The history shows the company’s aggregate cash outflow for dividends, not the dividend per share, dividend yield, or the date an investor receives a payment.
Calculation and source
Reported cash dividends paid
TickerStat standardizes cash dividends paid to common or ordinary shareholders from official cash-flow filings. Reported zero-dividend periods remain zero and are not treated as missing data. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...